📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
TAKE Solutions EOGM: Shifting Office to Maharashtra and New Auditor Appointment
TAKE Solutions held an Extra Ordinary General Meeting on March 7, 2026, to approve several key governance and operational changes. Shareholders voted on the regularization of two Non-Executive Directors and the appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following a casual vacancy. A significant special resolution was proposed to shift the company's registered office from Tamil Nadu to Maharashtra. The management also emphasized a strategic pivot toward AI-driven healthcare and diagnostics platforms.
Key Highlights
Approval for shifting the Registered Office from Tamil Nadu to Maharashtra via a Special Resolution.
Appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors to fill the vacancy caused by the resignation of M/s. Sundar Srini & Sridhar.
Regularization of Mr. Parmeshvar Dhangare and Mr. Vilas Munis as Non-Executive Non-Independent Directors.
The meeting was attended by 38 members out of a total shareholder base of 66,526 as of February 28, 2026.
Strategic focus reaffirmed on building scalable technology-led platforms in AI-driven healthcare and preventive care.
💼 Action for Investors
Investors should monitor the transition to the new registered office and any further disclosures regarding the auditor's resignation. The company's shift toward AI-driven healthcare is a long-term strategic move that requires tracking for execution milestones.
Centum Electronics Secures INR 566 Cr HAL Order; Expands Bengaluru Aerospace Facility
Centum Electronics has secured a significant two-phase order from HAL for AESA Radar Systems, valued at approximately INR 566 crore. The company's 9M-FY26 revenue mix shows a strong 50% contribution from the Defense, Space, and Aerospace sectors, with 30% of total revenue derived from high-value Build-to-Specification (BTS) projects. To support this growth, Centum has broken ground on a new systems integration facility at the KIADB Aerospace Park in Bengaluru. Management is also actively restructuring its European subsidiary to counter weak macro-economic conditions and subdued ER&D demand in that region.
Key Highlights
Secured a major AESA Radar Systems order from HAL worth INR 566 crore (INR 66 Cr in Phase 1 and INR 500 Cr in Phase 2).
Defense, Space, and Aerospace segments account for 50% of consolidated revenue as of 9M-FY26.
Commenced construction of a new dedicated facility for systems integration at KIADB Aerospace Park, Bengaluru.
Maintains a strong R&D focus with ~600 design engineers and 17 patents driving the BTS and ER&D verticals.
Strategic restructuring initiated for the overseas subsidiary to mitigate the impact of weak demand in the European market.
💼 Action for Investors
Investors should view Centum as a high-conviction play on India's defense indigenization, focusing on its transition from component manufacturing to complex system integration. Monitor the execution of the large HAL order and the margin improvements following the restructuring of the European operations.
Lupin's Ankleshwar Facility Receives US FDA Form-483 with 2 Observations
The U.S. FDA concluded a six-day inspection at Lupin's manufacturing facility in Ankleshwar, India, on March 07, 2026. The inspection resulted in the issuance of a Form-483 with two observations regarding manufacturing practices. Lupin has stated it will address these observations and respond to the regulator within the stipulated timeframe to ensure CGMP compliance. While the number of observations is low, the impact depends on their technical severity and the company's ability to remediate them quickly.
Key Highlights
U.S. FDA inspection conducted at the Ankleshwar facility from March 02 to March 07, 2026.
The inspection concluded with the issuance of a Form-483 containing 2 observations.
Lupin is required to respond to the U.S. FDA within the stipulated timeframe to address findings.
Company maintains commitment to CGMP standards across all manufacturing facilities.
💼 Action for Investors
Investors should monitor for the final classification of the inspection (VAI or OAI) as significant observations could lead to regulatory escalations. The low number of observations is generally manageable, but the specific nature of the findings will determine the long-term impact on US exports.
GSK Pharma to Appoint Ronojit Biswas as Whole-time Director & CFO for 3-Year Term
GlaxoSmithKline Pharmaceuticals Limited has initiated a postal ballot to seek shareholder approval for the appointment of Mr. Ronojit Biswas as a Whole-time Director and Chief Financial Officer. The proposed tenure is for three years, effective from April 1, 2026, to March 31, 2029. Shareholders can participate in the electronic voting process from March 9 to April 8, 2026, with final results expected by April 10, 2026. This leadership change is part of the company's planned management transition.
Key Highlights
Appointment of Mr. Ronojit Biswas as Whole-time Director and CFO for a 3-year term starting April 1, 2026.
E-voting period for shareholders is scheduled from March 9, 2026, to April 8, 2026.
The cut-off date for determining shareholder eligibility for voting was February 27, 2026.
The results of the postal ballot will be officially announced on or before April 10, 2026.
💼 Action for Investors
Investors should take note of the leadership transition and monitor the official announcement of voting results on April 10, 2026. No immediate portfolio action is required as this is a standard management appointment.
GSK Pharma to Appoint Ronojit Biswas as WTD & CFO for 3-Year Term
GlaxoSmithKline Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Ronojit Biswas as a Whole-time Director and Chief Financial Officer. The proposed appointment is for a period of three years, effective from April 1, 2026, to March 31, 2029. Shareholders can participate in the decision via remote e-voting, which is scheduled to take place between March 9 and April 8, 2026. The results of the ballot will be declared on or before April 10, 2026.
Key Highlights
Appointment of Mr. Ronojit Biswas as Whole-time Director and CFO for a 3-year term starting April 1, 2026
Remote e-voting period scheduled from March 9, 2026, to April 8, 2026
Cut-off date for determining shareholder voting eligibility was February 27, 2026
Final results of the postal ballot to be announced by April 10, 2026
💼 Action for Investors
This is a routine leadership appointment; investors should monitor the voting results for confirmation of the new CFO's tenure but no immediate action is required.
Avanti Feeds Q3 FY26: 9M PBT Jumps 32.7% to ₹698 Cr; RM Cost Headwinds Flagged for Q4
Avanti Feeds reported a robust 9M FY26 performance with consolidated PBT rising 32.7% YoY to ₹698 crores, supported by a 9.67% growth in gross income. For Q3 FY26, consolidated PBT grew 20.65% YoY to ₹222 crores, though revenue saw a seasonal QoQ decline of 12.78%. The shrimp processing division showed significant improvement, with Q3 PBT jumping to ₹52 crores from ₹18 crores YoY due to better realizations and lower freight costs. However, management cautioned that sharp spikes in raw material prices, particularly fish meal (up to ₹145/kg), will likely compress Q4 margins.
Key Highlights
Consolidated 9M FY26 PBT reached ₹698 crores, a 32.7% increase over the previous year's ₹526 crores.
Shrimp processing revenue for 9M FY26 grew 52% YoY to ₹1,296 crores, driven by a 28% volume growth.
Feed sales for 9M FY26 stood at 4,38,335 MT, with management targeting 5,55,000 MT for the full year.
Raw material costs are rising sharply; fish meal increased from ₹117/kg in Q3 to a current price of ₹145/kg.
Management revised FY26 PBT margin guidance to 14.5%-15% due to the recent surge in input costs.
💼 Action for Investors
Investors should remain positive on the strong 9M performance but must closely monitor the impact of rising fish meal and soya bean prices on Q4 profitability. The diversification into pet care and the turnaround in the processing segment provide long-term value, though short-term margin volatility is expected.
R Systems Declares Rs 6.00 Interim Dividend; Sets March 12 as Record Date
R Systems International Limited has declared an interim dividend of Rs. 6.00 per equity share for the year 2026. The company has fixed March 12, 2026, as the record date to determine eligible shareholders for this payout. Investors must ensure their tax-related documents and PAN details are updated by the record date to benefit from appropriate TDS rates. The dividend is scheduled to be paid to eligible shareholders on or before April 04, 2026.
Key Highlights
Interim dividend of Rs. 6.00 per equity share of Re. 1/- face value announced.
Record date for dividend eligibility is fixed as Thursday, March 12, 2026.
Dividend payment will be completed on or before April 04, 2026.
TDS of 10% applicable for resident shareholders with valid PAN; 20% for those without PAN.
Deadline for submitting tax exemption forms (15G/15H) is March 12, 2026.
💼 Action for Investors
Shareholders should verify that their PAN and bank account details are correctly updated with their Depository Participant by March 12 to ensure seamless dividend credit and correct tax treatment.
Hariom Pipe Seeks Approval for ₹270 Cr Solar Project RPT and Director Re-appointment
Hariom Pipe Industries has issued a postal ballot notice seeking shareholder approval for three key resolutions. The most significant is a material related party transaction of up to ₹270 crore with its subsidiary, Hariom Power and Energy Private Limited, to develop a solar power project. The company also seeks approval for transactions with Metal Mart Private Limited to improve operational efficiency and secure GST reimbursement subsidies for its Telangana Unit. Additionally, the board proposes the re-appointment of Mr. Rajender Reddy Gankidi as an Independent Director for a second five-year term.
Key Highlights
Proposed Material Related Party Transaction of up to ₹270 Crore with subsidiary HPEPL for solar energy development.
Investment aligns with ESG principles and a long-term vision for green steel manufacturing.
Transactions with Metal Mart Private Limited (MMPL) designed to avail mega subsidy benefits including GST reimbursement.
Re-appointment of Mr. Rajender Reddy Gankidi as Independent Director for a 5-year term starting May 15, 2026.
Remote e-voting period runs from March 09, 2026, to April 07, 2026, with results by April 09.
💼 Action for Investors
Investors should view the ₹270 crore solar investment as a positive move toward long-term energy cost reduction and ESG compliance. The potential for GST reimbursements through the MMPL transaction could provide a meaningful boost to operational margins in the near term.
Karnataka Bank Director Dr. D.S. Ravindran Resigns After Shareholder Rejection
Dr. D.S. Ravindran has resigned as a Non-Executive Independent Director of Karnataka Bank effective March 6, 2026. The resignation follows the rejection of his renomination for a second term by the bank's shareholders. Dr. Ravindran held significant roles, including Chairman of the IT Strategy Committee and member of the Audit Committee. He confirmed there are no other material reasons for his departure beyond the shareholder vote.
Key Highlights
Resignation of Dr. D.S. Ravindran effective from 09:00 PM on March 06, 2026.
Resignation was triggered by shareholders rejecting the resolution for his second-term renomination.
Vacated the chairmanship of the IT Strategy Committee and membership in the Audit Committee.
The director confirmed no other material reasons for resignation other than the shareholder vote outcome.
💼 Action for Investors
Investors should monitor the bank's upcoming appointments to fill the critical vacancies in the IT Strategy and Audit Committees. The shareholder dissent indicates active institutional oversight and scrutiny of board composition.
AU Small Finance Bank Receives RBI Relief on NOFHC Requirement for Universal Bank Transition
AU Small Finance Bank (AUBANK) has received a significant regulatory relaxation from the RBI regarding its transition to a Universal Bank. Previously, the RBI mandated that promoter shareholding must be held through a Non-Operative Financial Holding Company (NOFHC) for the transition. The RBI has now modified this, stating that an NOFHC will only be required if the bank or its promoters propose to establish any new group entities in the future. This simplifies the transition process and removes a major structural hurdle for the bank, which received its 18-month in-principle approval on August 7, 2025.
Key Highlights
RBI relaxed the mandatory NOFHC requirement for AU Bank's transition to a Universal Bank license.
NOFHC structure is now only applicable if the bank or promoters establish new group entities in the future.
The in-principle approval for the transition, granted on August 7, 2025, remains valid for a period of 18 months.
The bank will now submit its final application for the Universal Banking license under the revised guidelines.
Grant of the final license remains subject to RBI's assessment of compliance with regulatory instructions.
💼 Action for Investors
This is a positive development as it streamlines the corporate structure and reduces compliance complexity for the transition. Investors should maintain a positive outlook as the bank moves closer to obtaining a full Universal Banking license.
Servotech Shareholders Approve Independent Director Appointments with Over 99% Majority
Servotech Renewable Power System Limited has successfully passed two special resolutions via postal ballot as of March 6, 2026. Shareholders approved the regularization of Dr. Prabhat Kumar and the re-appointment of Mr. Meenakshisundaram Kolandaivel as Non-Executive Independent Directors. Both resolutions received overwhelming support, with approval ratings of 99.99% and 99.87% respectively. The voting saw a total turnout representing approximately 67.08% of the eligible voting power.
Key Highlights
Regularization of Dr. Prabhat Kumar as Independent Director approved with 15,14,97,221 votes (99.99% assent).
Re-appointment of Mr. Meenakshisundaram Kolandaivel approved with 15,13,11,877 votes (99.87% assent).
Total voter turnout represented 67.08% of the total shares held by the participating categories.
The voting process was conducted via remote e-voting between February 5 and March 6, 2026.
Promoter group showed 100% consensus in favor of both management resolutions.
💼 Action for Investors
Investors should take confidence in the strong shareholder consensus and stable board governance. No immediate portfolio changes are required as these are routine management appointments.
Shree Ram Proteins to Sell Land Undertaking for ₹30 Crore to Sova Agrotech
Shree Ram Proteins Limited (SRPL) has received shareholder approval to sell its land undertaking in Gondal, Rajkot, for a total consideration not exceeding ₹30 Crore. The sale is being made to Sova Agrotech Private Limited, a related party, with the transaction expected to be completed by April 2026. The company aims to use the proceeds to streamline its asset base, reduce maintenance costs, and focus on core business operations. The disposal was approved via a special resolution during the Extra Ordinary General Meeting held on March 5, 2026.
Key Highlights
Sale of land situated at Gondal, Rajkot for a consideration of up to ₹30 Crore.
Transaction is with Sova Agrotech Private Limited, a related party involving promoter Ms. Geetaben Lalitbhai Vasoya.
Expected completion date for the sale/disposal is set for April 2026.
Shareholder approval obtained via special resolution at the EGM held on March 5, 2026.
Strategic rationale includes streamlining assets and focusing on core business operations.
💼 Action for Investors
Investors should track the actual receipt of the ₹30 Crore and how the management redeploys this capital into core operations. Given it is a related party transaction, verify that the final valuation aligns with independent market benchmarks.
Lumax Auto Technologies Long-Term Credit Rating Upgraded to CRISIL AA/Stable
CRISIL Ratings has upgraded Lumax Auto Technologies Limited's long-term credit rating from 'CRISIL AA-/Positive' to 'CRISIL AA/Stable'. The short-term rating and commercial paper rating of Rs. 50 crore have been re-affirmed at 'CRISIL A1+', the highest safety category. The total bank loan facilities rated amount to Rs. 332 crore across multiple major lenders. This upgrade reflects the company's improved financial profile and sustained operational performance.
Key Highlights
Long-term credit rating upgraded to 'CRISIL AA/Stable' from 'CRISIL AA-/Positive'
Short-term and Commercial Paper ratings re-affirmed at 'CRISIL A1+'
Total bank loan facilities covered under the rating review amount to Rs. 332 crore
Commercial Paper programme of Rs. 50 crore maintains the highest safety rating for timely payments
Ratings involve major banks including HDFC, ICICI, YES Bank, and Kotak Mahindra
💼 Action for Investors
Investors should view this upgrade as a sign of strengthening financial health and improved creditworthiness, which may lead to lower borrowing costs. No immediate action is required, but the upgrade reinforces confidence in the company's balance sheet stability.
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoter Group
Neogen Chemicals' board has approved the issuance of 10 lakh equity shares at a price of Rs 1,610 per share, totaling Rs 161 crore. The shares are being issued on a preferential basis to Cadamba Solutions Private Limited, a promoter group entity. This issue price represents a significant 17.02% premium over the regulatory floor price of Rs 1,375.82. An Extraordinary General Meeting (EGM) is scheduled for March 29, 2026, to seek shareholder approval for this capital infusion.
Key Highlights
Issuance of 1,000,000 equity shares at Rs 1,610 each, aggregating to Rs 161 crore
The issue price is 17.02% higher than the SEBI-calculated floor price of Rs 1,375.82
The entire allotment is directed to Cadamba Solutions Private Limited, part of the promoter group
Post-allotment, the allottee will hold a 3.65% stake in the company
Extraordinary General Meeting (EGM) set for March 29, 2026, with a record date of March 20, 2026
💼 Action for Investors
Investors should view this as a positive signal as the promoters are increasing their stake at a significant premium to the floor price. Monitor the company's subsequent announcements regarding the specific utilization of these funds for growth or debt reduction.
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoters
Neogen Chemicals has announced an Extra Ordinary General Meeting (EGM) on March 29, 2026, to seek approval for a preferential issue of equity shares. The company plans to issue 10,00,000 shares to Cadamba Solutions Private Limited, a promoter group entity, at a price of Rs. 1,610 per share. This transaction will result in a total capital infusion of Rs. 161 crores into the company. The relevant date for determining the floor price was set as February 27, 2026, and the cut-off date for voting eligibility is March 20, 2026.
Key Highlights
Preferential allotment of 10,00,000 equity shares to promoter group entity Cadamba Solutions Private Limited.
Issue price fixed at Rs. 1,610 per share, including a premium of Rs. 1,600 per share.
Total fundraise amount of Rs. 161 crores to be received as 100% cash consideration.
EGM scheduled for March 29, 2026, with remote e-voting available from March 26 to March 28, 2026.
The capital infusion is subject to SEBI and stock exchange approvals following recent inter-se promoter transfers.
💼 Action for Investors
Investors should view this promoter-led capital infusion as a strong signal of confidence in the company's long-term growth. The non-debt funding will strengthen the balance sheet and support future expansion plans.
Neogen Chemicals to Raise ₹161 Crore via Preferential Issue to Promoter Group
Neogen Chemicals has convened an Extra Ordinary General Meeting (EGM) on March 29, 2026, to approve a preferential issue of equity shares. The company intends to issue 10,00,000 shares to Cadamba Solutions Private Limited, a member of the promoter group. The shares are priced at ₹1,610 each, including a premium of ₹1,600, resulting in a total fund infusion of ₹161 crore. This capital injection by the promoters indicates strong internal confidence in the company's future growth prospects.
Key Highlights
Issuance of 10,00,000 equity shares at a fixed price of ₹1,610 per share.
Total capital raise amounting to ₹161 crore from promoter group entity Cadamba Solutions Private Limited.
Relevant date for floor price determination set as February 27, 2026, in accordance with SEBI ICDR regulations.
EGM scheduled for March 29, 2026, to seek shareholder approval via special resolution.
The allotment is subject to a lock-in period as per SEBI regulations and requires specific regulatory exemptions due to prior inter-se transfers.
💼 Action for Investors
Investors should view the promoter's capital infusion at a significant premium as a positive signal of long-term commitment. Monitor the EGM results and subsequent disclosures regarding the specific utilization of these funds for expansion or debt reduction.
Poly Medicure 9M FY26 Revenue Up 9.1% to ₹1,341 Cr; Domestic Sales Grow 17.6%
Poly Medicure reported a 9.1% YoY increase in consolidated revenue to ₹1,340.7 crore for 9M FY26, driven by strong domestic growth of 17.6%. While Gross Profit margins improved to 68.8%, Operating EBITDA margins contracted slightly to 25.8% due to higher employee and acquisition-related expenses. The company is aggressively expanding into high-growth areas like Cardiology and Orthopaedics through recent acquisitions of Pendracare and Citieffe. With 15 manufacturing plants and a pipeline of 100+ products, the company aims to maintain its leadership as India's largest medical device exporter.
Key Highlights
Consolidated 9M FY26 revenue reached ₹1,340.7 crore, a 9.1% increase over the previous year.
Domestic revenue showed robust growth of 17.6%, while international revenue grew by 5.8%.
Gross Profit margin improved by 192 bps to 68.8%, though EBITDA margin dipped to 25.8%.
Strategic expansion into Cardiology and Orthopaedics via acquisitions of Pendracare (Netherlands) and Citieffe (Italy).
Manufacturing capacity stands at 1.8 billion+ devices per year across 15 global plants.
💼 Action for Investors
Investors should monitor the integration of recent European acquisitions and the ramp-up of the new Haridwar and upcoming Palwal plants. The shift towards high-complexity segments like Cardiology and Orthopaedics suggests potential for long-term margin expansion.
Manappuram Finance Appoints Sreekanth P V as President & Group Head of Operations and Digital
Manappuram Finance has appointed Mr. Sreekanth P V as President and Group Head of Operations, Services, and Digital, effective March 7, 2026. Mr. Sreekanth brings over 22 years of extensive experience in the financial services sector, including a significant tenure at Bajaj Finance Ltd as Deputy Executive Vice President of Digital Platforms. His background includes leadership roles at global institutions like HSBC and Standard Chartered, focusing on digital transformation and lending operations. This appointment is expected to bolster Manappuram's digital infrastructure and operational efficiency.
Key Highlights
Mr. Sreekanth P V appointed as President and Group Head - Operations, Services and Digital effective March 7, 2026
Appointee brings over 22 years of experience in operations, digital platforms, and product innovation
Previously held senior leadership roles at Bajaj Finance Ltd, including Deputy Executive Vice President – Digital Platforms
Extensive career history with major financial institutions including HSBC, GE Money, and Standard Chartered Bank
Educational background includes an MBA and B.Com (Honours) from Sri Sathya Sai Institute of Higher Learning
💼 Action for Investors
Investors should view this as a positive move to strengthen the leadership team with expertise from a top-tier competitor like Bajaj Finance. Monitor the company's progress in digital transformation and operational scaling under the new leadership.
Dollar Industries Receives NSE No-Objection for Composite Scheme of Arrangement with 9 Entities
Dollar Industries has received a 'No Objection' observation letter from the National Stock Exchange (NSE) regarding its proposed composite scheme of arrangement. The scheme involves the merger of eight transferor companies and the demerger of one entity (Dindayal Texpro Private Limited) into Dollar Industries. This regulatory clearance allows the company to move forward with filing the scheme before the National Company Law Tribunal (NCLT). The NSE has mandated specific disclosures, including updated financials not older than six months and a detailed rationale for the share-swap ratio.
Key Highlights
Received NSE 'No Objection' on March 6, 2026, for a scheme involving 8 transferor companies and 1 demerged entity.
The observation letter is valid for 6 months, requiring the company to file with NCLT by September 2026.
Mandatory disclosure of pre and post-scheme net worth and a detailed cost-benefit analysis for shareholders is required.
All equity shares to be issued under the proposed scheme must be in dematerialized form only.
Financials considered for the valuation report must not be more than 6 months old from the date of the NOC.
💼 Action for Investors
Investors should monitor the upcoming NCLT approval process and the specific share-swap ratios to assess potential equity dilution or value accretion. The consolidation of these entities is intended to create business synergies, but the final impact depends on the valuation of the private companies involved.
RHFL to Hold 7th Committee of Creditors Meeting on March 9, 2026
Reliance Home Finance Limited (RHFL) has scheduled the 7th meeting of its Committee of Creditors (CoC) for March 09, 2026, at 03:30 P.M. This meeting is a critical step in the ongoing Corporate Insolvency Resolution Process (CIRP) which was initiated on September 20, 2025. The company is currently under the management of Resolution Professional Umesh Balaram Sonkar. The meeting will be conducted via video conferencing to discuss the progress of the resolution plan for the corporate debtor.
Key Highlights
7th meeting of the Committee of Creditors (CoC) scheduled for March 09, 2026
Company has been under Corporate Insolvency Resolution Process (CIRP) since September 20, 2025
Meeting to be conducted via Video Conferencing at 03:30 P.M. IST
Resolution Professional Umesh Balaram Sonkar is overseeing the insolvency proceedings
Disclosure made under Regulation 30 of SEBI (LODR) Regulations
💼 Action for Investors
Investors should remain cautious as the company is in insolvency; equity value is typically at high risk during CIRP. Monitor the outcome of CoC meetings for any updates on potential resolution plans or liquidation.